



The European Commission has taken a lead role in supporting **research and innovation**, and in coordinating European and global research efforts, including preparedness for pandemics.

To support research and innovation, the Commission launched **two emergency calls** (expressions of interest), in **January and May**, for COVID-19 related research projects.

The **two calls** led to:




In addition, the **Innovative Medicines Initiative (IMI)** call led to:



For some of the **49 projects** the **grant agreements** have to be finalised.

The European Investment Bank in collaboration with the European Commission offered **€75 million** in debt financing to CureVac, an **innovative vaccines company** with a potential messenger RNA-based vaccine for coronavirus.



MAIN AREAS ADDRESSED

6 projects
received €19 million

To **improve preparedness and response** to disease outbreaks

8 projects
receiving €35.4 million

Geared towards **developing rapid diagnostics** for COVID-19

10 projects
receiving €103 million

To accelerate the **development of new treatments**

13 projects, expected
to receive €55.2 million

To develop **medical technologies, digital tools** and **artificial intelligence** analytics

4 projects, expected
to receive €22.1 million

For **repurposing of manufacturing** for medical supplies and equipment

4 projects, expected
to receive €28 million

To study the **behavioural, social and economic impact** of the outbreak

2 projects, expected
to receive €23 million

Will focus on **pan-European cohorts** and **international cooperation**

2 projects
received €5.7 million

To **develop** safe and effective **vaccines**

